---
search:
  boost: 3
---

# Hepatitis C

This is a subcategory of Infectious Disease Agents.

## Decision Tree

- [Antivirals - Hepatitis C](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMTY5QzZMMjg1VTdPOFo0Uk5QRVdYSDFCTCQlQCNjPTEkJUAjdD1n){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                              | Generic Name | Quantity | Time (Days) |
| :------------------------------------- | :----------- | :------: | :---------: |
| Mavyret <sup>PA</sup>                  |              |          |             |
| Pegasys <sup>PA</sup>                  |              |          |             |
| Ribavirin <sup>PA</sup>                |              |          |             |
| Sofosbuvir / Velpatasvir <sup>PA</sup> |              |          |             |

### Non-Preferred

| Non-Preferred           | Generic Name | Quantity | Time (Days) |
| :---------------------- | :----------- | :------: | :---------: |
| Harvoni                 |              |          |             |
| Ledipasvir / Sofosbuvir |              |          |             |
| Sovaldi                 |              |          |             |
| Vosevi                  |              |          |             |
| Zepatier                |              |          |             |

## Authorizations

**Length of Authorizations**: Dependent upon authorized course

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Clinical PA

Clinical PA Criteria

- Only regimens recommended by the American Association for the Study of Liver Diseases (AASLD) will be authorized
- Please see the [Hepatitis C Direct Acting Antiviral Prior Authorization Form](https://pharmacy.medicaid.ohio.gov/sites/default/files/HepC_PA_Form_20211119.pdf#overlay-context=prior-authorization){ :target="_blank" rel="noopener"} for criteria 

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response defined as not achieving SVR with guideline-recommended preferred drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Additional Information

- Requests for patients established on current therapy with prior payer (i.e., Commercial, Fee-for-Service, Managed Care Plan, etc) will be authorized with documentation
- Requests for regimens including pegylated Interferons must include close monitoring with periodic clinical and laboratory evaluations
- Requests for regimens including ribavirins must include documentation of at least two reliable forms of contraception being used during therapy

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=77&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"} 

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20231001+UPDL+Criteria+_v2.FINAL.pdf#page=83){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20231001_UPDL_V2.FINAL.hyperlinks_added.pdf#page=27){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/Quantity%20Limits.pdf){ :target="_blank" rel="noopener"}
